PDGFRB and neoplasm: Anlotinib is a TKI that inhibits both tumour angiogenesis and tumour cell proliferation by blocking VEGFR, FGFR, PDGFR and c-Kit simultaneously (Shen et al. 2018, Li et al. 2021).